KODIAK SCIENCES INC. Proceeds from Derivative Instrument, Investing Activities
KODIAK SCIENCES INC. (KOD) reported Proceeds from Derivative Instrument, Investing Activities of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-03-28.
Discontinued › Cash Flow › Investing Activities
us-gaap:ProceedsFromDerivativeInstrumentInvestingActivities · last filed 2024-03-28
- KODIAK SCIENCES INC. proceeds from derivative instrument, investing activities for the quarter ending 2023-12-31 was -$314.00K, a 150.97% decline year-over-year.
- KODIAK SCIENCES INC. proceeds from derivative instrument, investing activities for the quarter ending 2023-09-30 was $0.00.
- KODIAK SCIENCES INC. proceeds from derivative instrument, investing activities for the quarter ending 2022-12-31 was $616.00K.
- KODIAK SCIENCES INC. proceeds from derivative instrument, investing activities for the quarter ending 2022-09-30 was $0.00.
- KODIAK SCIENCES INC. proceeds from derivative instrument, investing activities for fiscal 2023 was $0.00, a 100.00% decline from fiscal 2022.
- KODIAK SCIENCES INC. proceeds from derivative instrument, investing activities for fiscal 2022 was $616.00K.
- KODIAK SCIENCES INC. proceeds from derivative instrument, investing activities for fiscal 2021 was $0.00.
- KODIAK SCIENCES INC. proceeds from derivative instrument, investing activities for fiscal 2020 was $0.00.
| Period end | Proceeds from Derivative Instrument, Investing Activities 3 month | Proceeds from Derivative Instrument, Investing Activities 6 month | Proceeds from Derivative Instrument, Investing Activities 9 month | Proceeds from Derivative Instrument, Investing Activities 12 month |
|---|---|---|---|---|
| 2023-12-31 | -$314.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | -$314.00K derived: sum of 2 quarters · filed 2024-03-28 | $0.00 10-K · filed 2024-03-28 | |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $314.00K 10-Q · filed 2023-11-14 | ||
| 2023-06-30 | $314.00K 10-Q · filed 2023-08-14 | |||
| 2022-12-31 | $616.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $616.00K derived: sum of 2 quarters · filed 2024-03-28 | $616.00K 10-K · filed 2024-03-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | $0.00 10-Q · filed 2023-11-14 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-14 | |||
| 2021-12-31 | $0.00 10-K · filed 2024-03-28 | |||
| 2020-12-31 | $0.00 10-K · filed 2023-03-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |